The FTSE 250 filters producer kept full-year its expectations unchanged.
In the quarter to September 30, 2020, the group saw revenue decline by 7%, with components down 20%, packaging down 8% and filters up 2%.
The company said its components and filters segments continued the improving trends seen in the second quarter, while the packaging division had a weaker period due to a reduction in elective surgeries and prescription levels, though the pharmaceutical and beauty markets are starting to slowly recover.
“We see Essentra as well positioned following the acquisition and fundraising and the shares look excellent value given the recovery prospects and potential for further M&A,” analysts at house broker Peel Hunt commented.
Shares rose 1% to 266.6p on Friday morning.
–Adds analyst comment, shares–